Skip to main content

Table 3 Symptom Improvement in 33 Assessable Patients

From: Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer

Response

Symptom Improvement

 

No.

%

CR+PR

1+5

18.2

SD

12

36.3

PD

0

0

Total

18

54.5